India’s healthcare sector records cumulative deal value of over INR 10,000 crore in Q2 FY26: EY‑Parthenon Report

Related topics

Mumbai, 15 January 2026: India’s healthcare sector delivered a resilient performance in Q2FY26, supported by rising demand for high-end clinical specialties, steady capacity expansion by hospital chains and strong consolidation in diagnostics, according to EY-Parthenon India’s Q2FY26 Healthcare Sector Update.

Mergers and acquisitions activity remained robust during the quarter. Q2FY26 saw over INR 10,000 crore worth of announced transactions across hospitals, diagnostics and specialty care, including buyouts, minority investments and cross-border acquisitions. Private equity and strategic investors continue to favour platforms with scalable regional footprints, strong clinical depth and technology-enabled delivery models.

From a valuation perspective, healthcare assets continue to command premium multiples, particularly in diagnostics and high-growth specialty segments. EV/EBITDA multiples for leading listed players ranged from the mid-teens to over 30x, reflecting investor confidence in long-term demand fundamentals and consolidation-led growth.

Average revenue per occupied bed (ARPOB) across leading hospital networks rose by 10–16% year-on-year, reflecting both pricing discipline and a shift toward higher-acuity procedures. Large hospital chains continued to expand aggressively. Collectively, leading hospital chains plan to add over 18,000 beds over the next three to five years, with a mix of greenfield projects and selective acquisitions.

Commenting on the analysis, Kaivaan Movdawalla, National Healthcare Leader, EY Parthenon India said “Q2FY26 underscores the structural strength of India’s healthcare sector. What stands out is the sustained shift toward high-acuity specialties such as oncology, cardiology and neurology, reflected in rising occupancy levels and double-digit ARPOB growth across leading hospital chains. At the same time, diagnostics players are moving decisively up the value chain, with accelerated investments in genomics, oncology and AI-led testing platforms. This combination of clinical depth, asset expansion and technology adoption positions the sector well for durable, long-term growth.”

The diagnostics segment continued to outperform, with leading chains reporting 10–22% year-on-year revenue growth in Q2FY26. Growth was driven by rising volumes in Tier 3 and Tier 4 cities, rapid expansion of B2C channels and increased demand for high-complexity testing. Several diagnostics players reported EBITDA margins in the range of 25–35%, supported by operating leverage and network optimisation.

Adding to it, Amit Gupta, Partner – Healthcare and Life Sciences Investment Banking, EY said, “Investor interest in healthcare remains robust, reflected in sustained buyouts, strategic acquisitions and private equity investments across hospitals, diagnostics and specialty care in Q2FY26. Investors are prioritising platforms with scalable regional footprints, robust unit economics and clear expansion pathways, especially into Tier 2 and Tier 3 markets. Integrated healthcare models and technology-enabled assets are increasingly favoured and are commanding premium valuations. As balance sheets improve and sector consolidation accelerates, deal momentum is expected to remain resilient, driven by both strategic and financial investors building long-term exposure to India’s healthcare sector.”

Investment focus within diagnostics shifted decisively toward advanced capabilities such as genomics, oncology and molecular testing. High-value and specialty tests now account for a growing share of revenues, while preventive and wellness programmes contributed up to 26% of quarterly revenues for some players.

Multi-specialty hospitals reported 9–28% year-on-year revenue growth, driven by higher occupancy, favourable case mix and sustained growth in complex specialties such as cardiology, oncology, neurology and gastroenterology. Average occupancy levels remained healthy, ranging between 54–77% for mature assets. International patient revenues and digital health offerings emerged as incremental growth levers, contributing up to 25–30% of revenues for select operators.

2026 Outlook

EY expects sector momentum to sustain over the remainder of FY26, supported by rising healthcare utilisation, capacity additions coming on stream and continued investor interest. While near-term margin pressures may persist for newly commissioned assets, medium-term fundamentals remain strong, underpinned by favourable demographics, expanding insurance coverage and increasing demand for specialised care.

Download the full pdf

PDF (1 MB)

About EY-Parthenon:

With over 6,500 EY-Parthenon professionals and 750+ partners across the globe, EY Parthenon is one of the largest strategy consultancies in the world. EY-P help CEOs and business leaders design and deliver transformative strategies across the entire enterprise, to help build long-term value to all stakeholders. With a result-oriented approach, EY-P teams bring experience and scale to each client, helping them to realize their strategies. By connecting teams and technologies from within EY-P and the broader EY ecosystem, EY-P can provide clients with corporate, transaction and turnaround strategies that are actionable and impactful and that help deliver long-term, sustainable value.

Whether it’s digital transformation, sector convergence and dislocation, or financial and operational complexities, EY-P teams bring data analytics, leading technology, and digital capabilities to a CEO’s toughest strategic issues. In doing so, EY Parthenon teams can move quickly from idea to implementation to help clients realize their strategy with speed and certainty; we call this Strategy Realized.

For more information about our organization, please visit https://www.ey.com/en_in/strategy/about-ey-parthenon